ATRX and neoplasm: According to this data, tumors with loss of nuclear ATRX and immunohistochemically negative IDH1 R132H should undergo additional sequencing for IDH1/2 and H3F3A irrespective of the patient’s age, as these markers are of great importance for further classification of tumor and choosing the appropriate therapeutic regimen.